Epithalon

Epithalon (also written Epitalon or AEDG, for the amino acids alanine, glutamic acid, aspartate, and glycine) is a synthetic four-amino-acid peptide developed from the composition of epithalamin, a pineal gland extract, and later confirmed as a natural component of the pineal polypeptide complex ^{21 8}. It is studied mainly in aging research: the most consistent findings involve telomerase activation in human cells and shifts in pineal melatonin and circadian signaling ^{29 15}. It is typically injected, although intranasal and oral routes appear in experimental work ^{28 11}.

The evidence base spans three decades, with much of it from one Russian research group. Independent replications of specific cell findings began appearing after 2022 ^{6 7 12}. No randomized controlled trial exists, so human evidence is limited to small observational or ex vivo studies ^{1 3}.

Studied areas

• Telomere maintenance and telomerase: the most replicated effect in human cell lines ^{29 6}.
• Circadian rhythm and melatonin output: normalization of clock genes and increased melatonin metabolite in humans ¹⁵.
• Neurogenesis and neuronal markers: increased stem-cell markers and partial protection of aged neurons ^{18 9}.
• Skin and fibroblast aging: reduced senescence markers and improved proliferation ^{22 35}.
• Retinal protection: protective effects in diabetic retinopathy and hereditary retinal degeneration models ^{7 32}.
• Cancer models and kidney function: tumor-suppressive and nephroprotective findings in animals ^{31 23}.
• Lifespan: extension in flies and rodents, without independent replication ^{34 27}.

Epithalon's best-replicated cellular effect is activation of telomerase, the enzyme that maintains the protective caps (telomeres) at the ends of chromosomes. In normal human epithelial and fibroblast cell lines, exposure produced dose-dependent telomere lengthening through increased hTERT, the catalytic subunit of telomerase ^{6 29}. In cancer cell lines, lengthening used a different process called alternative lengthening of telomeres (ALT), with only minimal ALT activity in normal cells ⁶. In human lymphocytes, the response looked like normalization rather than universal elongation: shorter telomeres lengthened in some donors while longer telomeres shortened ¹⁹.

The peptide is thought to act upstream of telomerase by influencing gene expression. Modeling suggests it binds linker histone proteins H1.3 and H1.6 at DNA-interacting sites, and treated stem cells showed increased production of neurogenic markers such as nestin, GAP43, beta-III tubulin, and doublecortin ¹⁸. Studies in lymphocytes from older adults also found decondensation of heterochromatin, the tightly packed DNA that silences genes ³⁷. In human buccal epithelium, downstream markers included reduced p16, p21, and p53, which are associated with cellular senescence and apoptosis, and increased TERF-1, prohibitin, SIRT1, and SIRT6 ¹⁰.

Other documented mechanisms include pineal and circadian regulation, antioxidant and mitochondrial protection, and immune modulation. In middle-aged humans, Epithalon raised urinary 6-sulfatoxymelatonin about 1.7-fold and normalized clock gene expression ¹⁵. In high-glucose-stressed retinal cells it reduced oxidative injury and restored wound healing ⁷, and in aged oocytes it reduced reactive oxygen species and improved mitochondrial membrane potential ¹². It also suppressed inflammatory TNF and IL-6 responses in human monocyte and macrophage cultures ¹³.

Epithalon's documented effects vary widely in strength. Telomerase activation in human cells is the most consistently replicated finding ^{6 29}. Human longevity and anti-cancer claims remain the least supported ^{1 3}.

Effect	What the research shows	Evidence base
Telomere maintenance	Dose-dependent telomerase and telomere extension in normal cell lines, with lymphocyte normalization in ex vivo human samples 6 19	In vitro and ex vivo human
Circadian and melatonin restoration	Raised urinary 6-sulfatoxymelatonin 1.7-fold and normalized CLOCK, CSNK1E, and CRY2 expression in middle-aged humans 15; melatonin and cortisol regulation in old monkeys 33	Small human observational plus animal
Antioxidant and mitochondrial protection	Lower reactive oxygen species, preserved mitochondrial membrane potential, and retinal wound healing in stressed cells 7 12	In vitro and animal
Neurogenesis support	Increased Nestin, GAP43, beta-III tubulin, and doublecortin 1.6-1.8-fold in stem cells 18; dendritic arborization in induced neurons from elderly donors 9	In vitro
Skin fibroblast aging	Reduced MMP-9 and caspase-dependent apoptosis, increased Ki-67 and CD98hc 22 35	In vitro and animal
Cancer model outcome	Reduced mammary tumor burden and HER-2/neu mRNA in transgenic mice 31, and inhibited colon carcinogenesis in rats 30	Animal models only
Kidney function	Normalized filtration in cisplatin-induced acute renal failure 23 and reduced proteinuria in aged rats 20	Animal models only
Lifespan	Extended lifespan in Drosophila and female rats 34 27	Animal studies, not independently replicated

A 2026 study also combined Epithalon with chaetocin as a senolytic approach, partially eliminating chemotherapy-resistant senescent cells and restoring response in a lymphoma model ². This is research-stage work, not an established effect.

No randomized trial has established an optimal dose, route, or cycle for Epithalon ^{1 3}. Published human abstracts do not report milligram doses, so the higher milligram figures below are practitioner consensus anchored to course-based human studies and animal schedules. The clearest published scaffold is an animal schedule of 1 microgram per mouse subcutaneously on days 1-5 of each month, which reduced mammary tumor burden and HER-2/neu mRNA 3.7-fold in transgenic mice ³¹. A human observational course raised urinary 6-sulfatoxymelatonin 1.7-fold over 10 days ¹⁵.

Regimen	Route	Dose	Pattern	Origin
Published mouse oncology and longevity schedule	Subcutaneous	1 microgram per mouse, about 0.04 mg/kg	Days 1-5 of each month for months	Animal study 31
Human circadian-restoration course	Parenteral	Daily course dosing	10 days	Observational study 15
Common community longevity course	Subcutaneous	5-10 mg once daily	10-20 days, repeated two to four times per year	Community protocols
Intranasal variant	Intranasal	0.5-1 mg once daily	10-20 day courses	Community protocols; central nervous system access is supported by animal data 28
Oral variant	Oral	5-20 mg once daily	10-20 day courses	Community protocols; absorption remains unproven 11

Fixed dosing rather than weight-based dosing dominates human and community practice. Evening administration is the prevailing community pattern because Epithalon's pineal and circadian effects align with the body's melatonin rhythm ¹⁵. No published morning-versus-evening human comparison exists. Continuous daily use beyond about 30 days is uncommon and not evidence-supported. The timeline card above summarizes the typical community longevity course.

Epithalon is supplied as a lyophilized, or freeze-dried, powder. Its two acidic side chains make it freely water-soluble, so no special solubilizing agent is required ⁸. The standard diluent is bacteriostatic water. The solution should be added slowly down the vial wall and swirled gently rather than shaken, because vigorous mixing can damage peptide chains.

For storage, unreconstituted vials are kept at 2-8°C for weeks to months, or frozen at -20°C for longer-term storage, protected from light and moisture. Once mixed, the solution is refrigerated at 2-8°C and ordinarily used within 14-30 days. For longer horizons, aliquoting and freezing is used, and repeated freeze-thaw cycles of one vial are avoided.

No published forced-degradation or long-term stability study exists for Epithalon ⁸. The peptide has been identified in stored formulated products, indicating that it can survive formulation and storage in solution under some conditions ²⁴. The interactive calculator in this section handles concentration and volume calculations for a chosen vial and dose.

No formal clinical interaction study has been conducted for Epithalon. What is known comes from mechanistic and animal work.

• Melatonin and circadian agents: Epithalon increases pineal melatonin output and circadian gene activity ^{15 33}. This combination is additive and commonly used in community protocols.
• Cholinesterase inhibitors: In vitro and preclinical work reports enhanced acetylcholinesterase and butyrylcholinesterase activity ⁸, which could theoretically reduce the effectiveness of drugs in this class.
• Immunosuppressants and anti-TNF biologics: Epithalon suppresses LPS-driven TNF and IL-6 in human monocyte and macrophage cultures ¹³, creating a theoretical additive immunosuppressive effect.
• Platinum chemotherapy: In rats, Epithalon normalized kidney function after cisplatin-induced acute renal failure ²³, suggesting a possible nephroprotective role rather than a contraindication.
• Anthracyclines and resistant disease: Combined with chaetocin, Epithalon helped eliminate therapy-induced senescent cells and restored chemosensitivity in a resistant lymphoma model ². This requires oncology supervision and remains experimental.
• LAT1, LAT2, and PEPT1 substrates: Epithalon binds these transporters strongly in molecular docking studies ¹¹. There is a theoretical competition with drugs that use the same transporters, including levodopa and gabapentin; community guidance often separates dosing by at least two hours.
• DNA-targeting therapies: Acidic-side-chain peptides like Epithalon can destabilize double-stranded DNA in biophysical studies ²⁵, but the direction of interaction with chemotherapy or radiation is unresolved.
• Anticoagulants and antiplatelets: Broader reviews class Epithalon among peptides that normalize hemostasis and cytokine expression ¹, so monitoring is sensible when stacked with blood-thinning agents.
• Antioxidant supplements: Effects on reactive oxygen species are likely additive with Epithalon's antioxidant activity ^{7 14}, with no adverse signal reported.

Among peptide-peptide interactions, Vilon is a notable contrast: in the same HER-2/neu mouse model where Epithalon reduced tumor burden, Vilon increased mammary cancer incidence and shortened tumor latency ³¹. Community guidance avoids that pair in cancer-risk contexts.

Published literature does not document tolerance, withdrawal, or rebound with Epithalon. The telomere response itself has a built-in ceiling: exposed lymphocytes moved toward the group mean rather than elongating indefinitely, which argues against a simple more-is-longer response ¹⁹. Telomerase induction is also transient in human cell lines ⁶, and the landmark animal efficacy studies used intermittent schedules of five consecutive days monthly rather than daily perpetual dosing ³¹.

Because cancer cell lines can lengthen telomeres through alternative lengthening of telomeres (ALT) under exposure ⁶, community guides adopt precautionary cycling limits rather than continuous use. A common pattern is 10-20 days on, followed by a 3-6 month break, with two to four cycles per year. Continuous runs beyond about 30 days are uncommon and not supported by long-term safety data ^{1 3}.

Signs that a protocol may be too extended include new or worsening insomnia or vivid dreams mid-course, plateau after two to three weeks, persistent injection-site reactions, or return to baseline. The pineal axis appears suited to pulsed use because it restores melatonin synthetic machinery rather than merely stimulating it ^{15 33}.

Epithalon appears in several long-running community stacks. The strongest mechanistic pairing is with melatonin, since Epithalon upregulates the pineal gland's own melatonin synthetic machinery and raises urinary 6-sulfatoxymelatonin ^{15 46}. Animal work combining melatonin and Epithalon under altered lighting found restored digestive enzyme dynamics without an adverse signal ⁴².

Pineal-thymus combinations are common: Epithalon is often combined with thymic peptide bioregulators such as Thymalin or Thymogen. These peptides share anti-inflammatory effects in monocyte models ¹³, and concurrent use is standard in the bioregulator tradition, though the combined immunomodulatory load has not been formally studied.

Growth hormone secretagogues such as ipamorelin, CJC-1295, sermorelin, and tesamorelin are common longevity stacks. The pineal and HPA axis is mechanistically distinct from the GH/IGF-1 axis, but no formal interaction data exist. Tissue and repair peptides GHK-Cu, BPC-157, and TB-500 have no known shared-mechanism conflict, and wound-healing stacks appear in community practice ²².

Vilon is a notable exception: in the same HER-2/neu transgenic mouse model where Epithalon reduced tumor burden and HER-2/neu expression, Vilon increased mammary cancer incidence and shortened tumor latency ³¹, so community guidance avoids that pair in cancer-risk contexts. DSIP overlaps the pineal and circadian profile but has weaker translational support, and Semax/Selank have no interaction data.

In the United States, Epithalon is not FDA-approved for any indication, is not scheduled under the Controlled Substances Act, and has no randomized controlled trial program ^{1 3}. Availability runs through compounding or research-use channels, and regulatory reviews classify it among investigational, non-approved peptides ¹. European enforcement work has identified the peptide in illegal pharmaceutical preparations marketed for aging, cancer, and retinitis pigmentosa ²⁴.

Internationally, it has no EMA or MHRA marketing authorization, is not registered by the TGA in Australia, and is not authorized in Canada. In Russia it originated as part of the Khavinson Peptides bioregulator line and is commercialized as a parapharmaceutical or supplement ⁸.

For sports, Epithalon is not listed as a controlled substance and no validated anti-doping detection method or sanctions appear in the reviewed literature. However, because it lacks government approval for human therapeutic use, it may fall under WADA's S0 category for non-approved substances ^{1 3}. Competitive use is generally discouraged on that basis.

Reported side effects appear limited, but most safety data come from animal studies and small human observations without systematic adverse-event capture ¹. The expected on-target effects are sleep and circadian changes: increased urinary 6-sulfatoxymelatonin and normalized clock genes in people with reduced pineal function ¹⁵, with users often describing altered sleep onset, vivid dreams, and transient grogginess early in a course.

Uncommon or variable effects include:

• Bidirectional telomere response: In lymphocytes from 11 men, five lengthened and two shortened, a normalization pattern dependent on baseline length ¹⁹.
• Genotype-dependent response: Antimutagenic protection appeared only in white mice, not grey mice, indicating strain variability ⁴⁴.
• Renal function shifts: In aged rats, Epithalon reduced proteinuria but also lowered glomerular filtration rate by about 21%, with no nephrotoxic pathology ²⁰.
• Immune modulation: It induces TNF tolerance and suppresses inflammatory cytokines in monocyte cultures ¹³, raising a theoretical but unproven concern about muted acute infection responses.

Rare or theoretical concerns include cancer cells using ALT to lengthen telomeres under exposure ⁶; animal cancer models are generally tumor-suppressive ^{27 30 31}, but active malignancy remains a caution zone. Placental transfer has been shown in rabbits, so pregnancy and breastfeeding are contraindications ³⁶. Counterfeit products also circulate in unlicensed channels ²⁴, highlighting the need for verified sourcing.

Monitoring in research or clinical settings tends to include kidney function testing before and after cycles, sleep logs, and standard age-appropriate cancer screening ^{15 20}. No long-term human safety data exist, and continuous use beyond cycling windows is unstudied ³.